Ads
related to: Dupixent Eczema and Sales- FAQs
Find Answers To Your Questions
& Understand Treatment Now
- Getting Started
Learn More About Dosing Schedules
Find Answers To Your Questions
- Patient Support
Hear From The Ambassadors—
How This Treatment Option Works
- Sign Up
Apply Or Activate Your Card—
Find Out If You're Eligible Today.
- Home
Official Patient Website—
Get Treatment Info Today.
- Treatment Support
Discover Educational Resources
& Get Financial Support Information
- FAQs
Search results
Sanofi's Dupixent gets U.S. approval to treat eczema in young children
Reuters via Yahoo News· 2 years agoDupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi...
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Zacks via Yahoo Finance· 1 year agoSanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat...
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
Investor's Business Daily· 3 months agoSanofi stock undercut its 50-day line Thursday despite Dupixent outperformance as its earnings...
Sanofi forecasts moderate profit growth on Dupixent demand
Reuters via Yahoo News· 1 year ago(Reuters) -Sanofi forecast moderate earnings growth that undershot expectations, saying demand for...
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Investor's Business Daily· 6 months agoRegeneron Pharmaceuticals and Sanofi said Monday their blockbuster drug, Dupixent, significantly...
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks via Yahoo Finance· 2 months agoASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
Benzinga via Yahoo Finance· 1 year agoFrench drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in...
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Investor's Business Daily· 1 year agoRegeneron stock surged Friday on stronger-than-expected metrics, though its partner Sanofi posted a...
Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars
Investor's Business Daily· 1 year agoSanofi and Regeneron Pharmaceuticals' asthma drug Dupixent succeeded in a final-phase study of...
Sanofi Raises Profit Guide And Reverses A Drug-Pricing Pitfall
Investor's Business Daily· 2 years agoSanofi stock ended flat Thursday — reversing earlier declines — despite lifting its profit guidance...
Ads
related to: Dupixent Eczema and Sales